Health Care

Leahy presses anti-overdose drug’s maker on price hike

Sen. Patrick Leahy, D-Vt., along with 30 Democratic colleagues, is demanding answers from a pharmaceutical company that has increased the price of a lifesaving anti-opioid drug injector more than sixfold over the last two years.

In January, Kaiser Health News reported that Kaleo Pharmaceuticals, a Virginia-based company, had greatly increased the price of its anti-overdose injector called Evzio. The company has raised the price of its twin-pack of the injectors — which deliver naloxone to people who overdosed — from $690 in 2014 to $4,500 in 2016.

Patrick Leahy
Sen. Patrick Leahy, D-Vt. File photo by Alicia Freese/VTDigger
In a blistering letter sent Wednesday to Kaleo Pharmaceuticals CEO Spencer Williamson, Leahy and fellow Democrats said the hike “threatens to price-out families and communities that depend on naloxone to save lives.”

“This drug is now in the hands of first responders and families struggling with substance use disorder across the country,” the letter reads. “It is particularly needed in rural areas where access to life-saving emergency services can be limited.”

According to the Food and Drug Administration, Evzio accounted for nearly 20 percent of the naloxone dispensed through retail outlets between 2015 and 2016, and for nearly half of all naloxone products prescribed to patients between age 40 and 64 — the group that represents the bulk of naloxone users. Evzio is one of only two FDA-approved naloxone products, the other being the nasal spray Narcan.

More than 30,000 people died from opioid overdoses in America last year, and a recent Seven Days investigation found Vermont deaths in 2016 reached a record high of 100.

In July, President Barack Obama signed into law the Comprehensive Addiction and Recovery Act, which instructed the Department of Health and Human Services to re-examine prescription policies in the United States and enacted more stringent FDA requirements for opioids to be approved for new applications. Another provision of the law, written by Leahy, expanded availability of naloxone in rural areas.

“At a time when Congress has worked to expand access to naloxone products and to assist state and local communities to equip first responders with this life-saving drug, this startling price hike is very concerning,” the senators wrote.

The letter asks Kaleo to fully explain its pricing structure for the naloxone injector and to account for whether increased production costs contributed to the price spike. The senators also sought additional details regarding Kaleo’s contention that it donates the drug to cities, rehabilitation programs and first responders.

“How many devices does Kaleo set aside for your donation program compared to your total production?” the letter asks.

Kaiser reported that, in addition to the surge in price for Kaleo’s injector, the cost of naloxone has roughly doubled over the last few years as the demand for the drug has increased.

If you read us, please support us.

Comment Policy requires that all commenters identify themselves by their authentic first and last names. Initials, pseudonyms or screen names are not permissible.

No personal harrassment, abuse, or hate speech is permitted. Comments should be 1000 characters or fewer.

We moderate every comment. Please go to our FAQ for the full policy.

Jasper Craven

About Jasper

Jasper Craven is VTDigger’s political reporter. A Vermont native, he first discovered his love for journalism at the Caledonian Record. He double-majored in print journalism and political science at Boston University, and worked in the Boston Globe’s Metro and Investigative units. While at the Globe he collaborated on Shadow Campus, a three-part investigative series focused on greed and mismanagement in Boston’s off-campus student housing market. The series was a finalist for the 2015 Pulitzer Prize.
He also spent two years at MuckRock, a news sited dedicated to investigation and analysis of government documents. 

Craven covered Vermont’s U.S. Congressional delegation for the Times Argus in the summer of 2014, and worked as a Metro reporter for the Chicago Tribune before joining the staff of VTDigger.

Email: [email protected]

Follow Jasper on Twitter @Jasper_Craven

Latest stories by Jasper

Recent Stories

Thanks for reporting an error with the story, "Leahy presses anti-overdose drug’s maker on price hike"
  • Dave Bellini

    These drug company executives are as greedy and arrogant as the tsars. Congress should change the patient laws, outlaw price gouging and back it up with a fast-track death penalty. I have worked with convicted criminals for 4 decades. Few, are as disgusting as these greedy drug makers.

    • Neil Johnson

      “I have worked with convicted criminals for 4 decades. Few, are as disgusting as these greedy drug makers” Truer words have seldom been spoken, you nailed it!

  • rosemariejackowski

    How is it that addicts can get drugs, but chronic pain patients can’t ?

    • Neil Johnson

      Because the black market is more free than our legal market. When Leahy and crew allow monopolies to be formed there is no competition. When we have so many drug dealers operating outside the control of our government you have more choices at a lower cost..:)…..of course you don’t always get what you pay for….